Mitigation and reversal of intestinal fibrosis and inflammation by inhibition of TL1A function
US11434296B2 · kind B2 · utility
2Cited by
5References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 21, 2020 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | Mar 31, 2040 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.